{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:51:06Z","timestamp":1772509866436,"version":"3.50.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100013327","name":"H. Lundbeck A\/S","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013327","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Neuropsychopharmacology"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.euroneuro.2020.09.636","type":"journal-article","created":{"date-parts":[[2020,10,9]],"date-time":"2020-10-09T09:03:17Z","timestamp":1602234197000},"page":"70-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Add-on benzodiazepine treatment in patients with major depressive disorder \u2013 results from a European cross-sectional multicenter study"],"prefix":"10.1016","volume":"41","author":[{"given":"Markus","family":"Dold","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucie","family":"Bartova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gernot","family":"Fugger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marleen Margret Mignon","family":"Mitschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander","family":"Kautzky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Frey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Montgomery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Zohar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julien","family":"Mendlewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Souery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Fabbri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alessandro","family":"Serretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siegfried","family":"Kasper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.euroneuro.2020.09.636_bib0001","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0269881114525674","article-title":"Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: a revision of the 2005 guidelines from the British association for psychopharmacology","volume":"28","author":"Baldwin","year":"2014","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0002","doi-asserted-by":"crossref","first-page":"77","DOI":"10.3109\/13651501.2012.667114","article-title":"Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care","volume":"16","author":"Bandelow","year":"2012","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0003","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1080\/15622975.2019.1635270","article-title":"Results of the European Group for the Study of Resistant Depression (GSRD) - basis for further research and clinical practice","volume":"20","author":"Bartova","year":"2019","journal-title":"World J. Biol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0004","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.euroneuro.2015.07.021","article-title":"Combination of intravenous S-ketamine and oral tranylcypromine in treatment-resistant depression: a report of two cases","volume":"25","author":"Bartova","year":"2015","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0005","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/13651501.2017.1306082","article-title":"Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines","volume":"21","author":"Bauer","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0006","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.jad.2013.05.054","article-title":"Patterns of benzodiazepine and antidepressant use among middle-aged adults. the Brazilian longitudinal study of adult health (ELSA-Brasil)","volume":"151","author":"Brunoni","year":"2013","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0007","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881115581093","article-title":"Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2008 British Association for Psychopharmacology guidelines","volume":"29","author":"Cleare","year":"2015","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0008","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1016\/j.jad.2008.01.011","article-title":"Clinical factors influencing the prescription of antidepressants and benzodiazepines: results from the European study of the epidemiology of mental disorders (ESEMeD)","volume":"110","author":"Demyttenaere","year":"2008","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0009","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1093\/ijnp\/pyy009","article-title":"Major depression and the degree of suicidality: results of the European Group for the Study of Resistant Depression (GSRD)","volume":"2","author":"Dold","year":"2018","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"1","key":"10.1016\/j.euroneuro.2020.09.636_bib0010","doi-asserted-by":"crossref","first-page":"17m12090","DOI":"10.4088\/JCP.17m12090","article-title":"Psychotic features in patients with major depressive disorder - a report from the European Group for the Study of Resistant Depression","volume":"80","author":"Dold","year":"2019","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0011","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/j.euroneuro.2018.10.003","article-title":"Clinical factors associated with augmentation treatment with second-generation antipsychotics and lithium in major depression - Results from a European multicenter study","volume":"28","author":"Dold","year":"2018","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0012","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.euroneuro.2017.05.004","article-title":"The impact of comorbid post-traumatic stress disorder in patients with major depressive disorder on clinical features, pharmacological treatment strategies, and treatment outcomes - Results from a cross-sectional European multicenter study","volume":"27","author":"Dold","year":"2017","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0013","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/acps.12870","article-title":"Clinical correlates of augmentation\/combination treatment strategies in major depressive disorder","volume":"137","author":"Dold","year":"2018","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0014","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.jad.2017.10.033","article-title":"Low comorbid obsessive-compulsive disorder in patients with major depressive disorder - Findings from a European multicenter study","volume":"227","author":"Dold","year":"2017","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jpsychires.2017.02.020","article-title":"Clinical characteristics and treatment outcomes of patients with major depressive disorder and comorbid anxiety disorders - results from a European multicenter study","volume":"91","author":"Dold","year":"2017","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0016","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/13651501.2016.1248852","article-title":"Evidence-based pharmacotherapy of treatment-resistant unipolar depression","volume":"21","author":"Dold","year":"2017","journal-title":"Int. J. Psychiatry Clin. Pract."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0017","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1016\/j.euroneuro.2016.10.005","article-title":"Pharmacological treatment strategies in unipolar depression in European tertiary psychiatric treatment centers \u2013 a pharmacoepidemiological cross-sectional multicenter study","volume":"26","author":"Dold","year":"2016","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD001026","article-title":"Antidepressant plus benzodiazepine for major depression","author":"Furukawa","year":"2001","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0019","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1056\/NEJMoa1815981","article-title":"Trial of SAGE-217 in patients with major depressive disorder. Reply","volume":"381","author":"Gunduz-Bruce","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0020","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","article-title":"A rating scale for depression","volume":"23","author":"Hamilton","year":"1960","journal-title":"J. Neurol. Neurosurg. Psychiatr."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0021","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.jad.2015.03.021","article-title":"Dose equivalents of antidepressants: evidence-based recommendations from randomized controlled trials","volume":"180","author":"Hayasaka","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0022","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1007\/s40262-019-00801-0","article-title":"SAGE-217, a novel GABAA receptor positive allosteric modulator: clinical pharmacology and tolerability in randomized phase I dose-finding studies","volume":"59","author":"Hoffmann","year":"2020","journal-title":"Clin. Pharmacokinet"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0023","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/acps.12959","article-title":"Clinical factors predicting treatment resistant depression: affirmative results from the European multicenter study","volume":"139","author":"Kautzky","year":"2019","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0024","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1017\/S1461145711000745","article-title":"Increase of antipsychotic medication in depressive inpatients from 2000 to 2007: results from the AMSP International Pharmacovigilance Program","volume":"15","author":"Konstantinidis","year":"2012","journal-title":"Int. J. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0025","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1038\/s41398-019-0460-3","article-title":"Prognosis and improved outcomes in major depression: a review","volume":"9","author":"Kraus","year":"2019","journal-title":"Transl. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0026","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s12991-019-0248-0","article-title":"All-cause mortality in patients with treatment-resistant depression: a cohort study in the US population","volume":"18","author":"Li","year":"2019","journal-title":"Ann. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0027","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1038\/mp.2010.120","article-title":"The GABAergic deficit hypothesis of major depressive disorder","volume":"16","author":"Luscher","year":"2011","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0028","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1016\/j.jad.2020.02.023","article-title":"The identification, assessment and management of difficult-to-treat depression: an international consensus statement","volume":"267","author":"McAllister-Williams","year":"2020","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0029","doi-asserted-by":"crossref","first-page":"1058","DOI":"10.1016\/S0140-6736(18)31551-4","article-title":"Brexanolone injection in post-partum depression: two multicentre, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"392","author":"Meltzer-Brody","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0030","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1001\/archgenpsychiatry.2009.175","article-title":"National trends in psychotropic medication polypharmacy in office-based psychiatry","volume":"67","author":"Mojtabai","year":"2010","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0031","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Montgomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0032","article-title":"Antidepressants plus benzodiazepines for adults with major depression","volume":"6","author":"Ogawa","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0033","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/JCP.0b013e318217b4c4","article-title":"Benzodiazepines and adequacy of initial antidepressant treatment for depression","volume":"31","author":"Pfeiffer","year":"2011","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0034","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1176\/ajp.148.6.757","article-title":"Long-term benzodiazepine users 3 years after participation in a discontinuation program","volume":"148","author":"Rickels","year":"1991","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0035","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1177\/070674371506000105","article-title":"Depression and employment status in primary and tertiary care settings","volume":"60","author":"Rizvi","year":"2015","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0036","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jad.2015.07.040","article-title":"Correlates of benzodiazepine use in major depressive disorder: the effect of anhedonia","volume":"187","author":"Rizvi","year":"2015","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0037","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.euroneuro.2012.02.006","article-title":"European Group for the Study of Resistant Depression (GSRD)\u2013where have we gone so far: review of clinical and genetic findings","volume":"22","author":"Schosser","year":"2012","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0038","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.euroneuro.2009.11.011","article-title":"Outcomes of 1014 naturalistically treated inpatients with major depressive episode","volume":"20","author":"Seemuller","year":"2010","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0039","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1017\/S1461145708009139","article-title":"The controversial link between antidepressants and suicidality risks in adults: data from a naturalistic study on a large sample of in-patients with a major depressive episode","volume":"12","author":"Seemuller","year":"2009","journal-title":"Int. J. Neuropsychopharmacol."},{"issue":"Suppl 20","key":"10.1016\/j.euroneuro.2020.09.636_bib0040","first-page":"22","article-title":"The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0041","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9061938","article-title":"Benzodiazepines reduce relapse and recurrence rates in patients with psychotic depression","volume":"9","author":"Shiwaku","year":"2020","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0042","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0924-977X(98)00004-2","article-title":"Treatment resistant depression: methodological overview and operational criteria","volume":"9","author":"Souery","year":"1999","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0043","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.4088\/JCP.v68n0713","article-title":"Clinical factors associated with treatment resistance in major depressive disorder: results from a European multicenter study","volume":"68","author":"Souery","year":"2007","journal-title":"J. Clin. Psychiatry"},{"issue":"Suppl 6","key":"10.1016\/j.euroneuro.2020.09.636_bib0044","first-page":"16","article-title":"Treatment-resistant depression","volume":"67","author":"Souery","year":"2006","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0045","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1176\/appi.ajp.163.1.28","article-title":"Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice","volume":"163","author":"Trivedi","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0046","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1176\/appi.ajp.161.4.654","article-title":"Benzodiazepine use among depressed patients treated in mental health settings","volume":"161","author":"Valenstein","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0047","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.jad.2015.09.013","article-title":"Major depression treatment in Germany-descriptive analysis of health insurance fund routine data and assessment of guideline-adherence","volume":"189","author":"Wiegand","year":"2016","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0048","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/S0924-977X(02)00174-8","article-title":"Clonazepam in the long-term treatment of patients with unipolar depression, bipolar and schizoaffective disorder","volume":"13","author":"Winkler","year":"2003","journal-title":"Eur. Neuropsychopharmacol."},{"key":"10.1016\/j.euroneuro.2020.09.636_bib0049","doi-asserted-by":"crossref","DOI":"10.1016\/j.ynstr.2019.100196","article-title":"Neurosteroids as novel antidepressants and anxiolytics: GABA-A receptors and beyond","volume":"11","author":"Zorumski","year":"2019","journal-title":"Neurobiol. Stress"}],"container-title":["European Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20309093?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924977X20309093?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:57:20Z","timestamp":1760378240000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924977X20309093"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":49,"alternative-id":["S0924977X20309093"],"URL":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.09.636","relation":{},"ISSN":["0924-977X"],"issn-type":[{"value":"0924-977X","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Add-on benzodiazepine treatment in patients with major depressive disorder \u2013 results from a European cross-sectional multicenter study","name":"articletitle","label":"Article Title"},{"value":"European Neuropsychopharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euroneuro.2020.09.636","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier B.V. and ECNP. All rights reserved.","name":"copyright","label":"Copyright"}]}}